Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China’s State FDA Sees Big Challenges In Food And Drug Administration

This article was originally published in PharmAsia News

Executive Summary

After last year's governmental reform, China's State FDA is now responsible for supervising five kinds of public health-related products, namely, consumer food, health care products, cosmetics, drugs and medical devices. It is facing big challenges in food and drug safety supervision. Key issues include the problem of completely overhauling and standardizing the fragmented food and drug industry beleaguered with diverse small segments, varied levels of industrialization and focus. In addition, manufacturing of counterfeit drugs and sale of such medicines online to remote areas put more pressure on monitoring. However, SFDA will step up efforts to improve legislation, raise standards and tighten supervision, with special focus on investigating fake drugs posing as medicine, illegitimate additives in patented TCM and illegal drug advertisements. (Click here for more - Chinese Language)

You may also be interested in...



EU Scientific Committee Affirms Safety Of Anti-Dandruff Zinc Pyrithione Under Threat Of Cosmetic Ban

The Scientific Committee for Consumer Safety upholds that zinc pyrithione is safe for use in rinse-off anti-dandruff hair products at levels up to 1%. In recent years, the cosmetics industry has pushed for a 2% ceiling on ZPT content in that capacity – with considerable inroads made. Where that proposal now stands vis-à-vis the ingredient’s pending CMR 1B classification and shifting political sands is uncertain.

Otsuka Dermatitis Candidate Looks Good At Phase III

New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.

US FDA Decides Against Zolgensma Data Integrity Penalties As Novartis Bureaucratizes AveXis

Company’s promise to be more forthright, along with quality culture and policy upgrades, may have helped sway agency.

UsernamePublicRestriction

Register

SC071038

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel